GDNSF
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
Vireo Growth has been rated Neutral with a Composite score of 49.8 in the latest analysis. Within this band, fundamentals present the strongest pillar at 66.0, showing relative robustness compared to regulatory, market, and editorial pillars. The Neutral rating reflects low conviction at 1 out of 5, indicating a cautious stance driven by significant uncertainties. The Neutral classification suggests limited immediate upside potential, balanced by moderate strengths in financial parameters despite the cash runway's "stretched" condition.
Recent data depict a complex financial landscape for Vireo Growth. Year-over-year revenue growth registers at a healthy pace, while gross and operating margins indicate profitability hurdles due to elevated costs. However, a positive EBITDA amidst a net loss highlights efforts toward operational efficiency. The fundamental strengths are tempered by a broader backdrop of a "stretched" financial condition, emphasizing ongoing challenges in liquidity and solvency, which persist despite positive earnings before interest, taxes, depreciation, and amortization.
Looking forward, investors should monitor the fundamentals pillar closely, as it continues providing optimistic signals amidst challenges. Revenue growth and efficient margin management will remain key indicators to watch, as improvements here could eventually lead to a reevaluation of the financial condition. Any advancements in these areas could steer a shift in conviction, offering new directions in the company's financial trajectory.
- IR / PR agency
- Alpha IR Group
- IR email
- investor@vireogrowth.com
- IR page
- Investor relations
- Headquarters
- 209 South 9th St., Minneapolis, MN 55402
- Phone
- (844)484-7366
- CEO
- John Mazarakis
- CFO
- Tyson Macdonald
- SEC CIK
- 0001771706
- Website
- Company website
- Market cap
- $56.7M
- Enterprise value
- $141.2M
- Price to book
- 1.22
- Price to sales
- 0.61
- EV / EBITDA
- 6.29
- Revenue (TTM)
- $93.1M
- Gross profit (TTM)
- $19.8M
- EBITDA
- $16.1M
- Operating margin
- 19.8%
- Profit margin
- -25.6%
- Rev growth YoY
- 26.2%
- Return on equity
- -1890.8%
- Return on assets
- 5.3%
- EPS (TTM)
- $-0.17
- EPS est. current year
- $-0.12
- Wall St. target price
- $0.55
- Shares outstanding
- 112.3M
- Insider ownership
- 17.4%
- Institutional ownership
- 15.3%
- Beta
- 1.42
- Full-time employees
- 385
- GICS sector
- Healthcare
- GICS industry
- Drug Manufacturers - Specialty & Generic
- Filing portal
- SEC EDGAR
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for GDNSF (GDNSF)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for GDNSF (GDNSF), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for GDNSF are maintained by Cannabis Investor News and refreshed throughout the trading day.